These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 38670444

  • 1. The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women.
    Caritis SN, Dodeja P, Sharma S, Zhao W, Venkataramanan R.
    Am J Obstet Gynecol; 2024 Apr 25. PubMed ID: 38670444
    [Abstract] [Full Text] [Related]

  • 2. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
    Caritis SN, Costantine MM, Clark S, Stika CS, Kiley JW, Metz TD, Chauhan SP, Venkataramanan R, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers Network.
    Am J Obstet Gynecol MFM; 2023 Jul 25; 5(7):100980. PubMed ID: 37100349
    [Abstract] [Full Text] [Related]

  • 3. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
    Caritis SN, Venkataramanan R, Thom E, Harper M, Klebanoff MA, Sorokin Y, Thorp JM, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Grobman WA, Mercer BM, Sciscione A, Rouse DJ, Ramin S, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network.
    Am J Obstet Gynecol; 2014 Feb 25; 210(2):128.e1-6. PubMed ID: 24113254
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB, McIntire DD, Leveno KJ.
    Am J Obstet Gynecol; 2021 Feb 25; 224(2):175-186. PubMed ID: 33035472
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
    Della Torre M, Enakpene C, Ravangard S, DiGiovanni L, Deyo K, Whelan A, Sutherland M, Fischer J.
    Am J Obstet Gynecol MFM; 2019 Nov 25; 1(4):100051. PubMed ID: 33345841
    [Abstract] [Full Text] [Related]

  • 7. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW.
    Am J Obstet Gynecol; 2016 Nov 25; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [Abstract] [Full Text] [Related]

  • 8. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S, Freedman A, Adams M, Hirsch E, Ernst LM.
    Am J Obstet Gynecol; 2024 Apr 25; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
    Ward A, Greenberg V, Valcarcel B, Boelig RC, Al-Kouatly HB, Berghella V.
    Am J Obstet Gynecol MFM; 2020 Aug 25; 2(3):100124. PubMed ID: 33345870
    [Abstract] [Full Text] [Related]

  • 11. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML, Caritis SN, Jablonski KA, Reddy UM, Sorokin Y, Manuck T, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Peaceman AM, Mercer BM, Sciscione A, Rouse DJ, Ramin SM, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2017 Sep 25; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [Abstract] [Full Text] [Related]

  • 12. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar 25; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 13. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC, Locci M, Saccone G, Gragnano E, Berghella V.
    Am J Obstet Gynecol MFM; 2022 Sep 25; 4(5):100658. PubMed ID: 35562009
    [Abstract] [Full Text] [Related]

  • 14. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ.
    Am J Obstet Gynecol; 2017 Jun 25; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [Abstract] [Full Text] [Related]

  • 15. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC, Schoen CN, Frey H, Gimovsky AC, Springel E, Backley S, Berghella V.
    Am J Obstet Gynecol; 2022 May 25; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [Abstract] [Full Text] [Related]

  • 16. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA.
    Am J Obstet Gynecol; 2017 Sep 25; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [Abstract] [Full Text] [Related]

  • 17. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
    Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, SMFM Publications Committee.
    Am J Obstet Gynecol; 2023 Jul 25; 229(1):B2-B6. PubMed ID: 37061078
    [Abstract] [Full Text] [Related]

  • 18. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
    Stringer EM, Vladutiu CJ, Manuck T, Verbiest S, Ollendorff A, Stringer JS, Menard MK.
    Am J Obstet Gynecol; 2016 Jul 25; 215(1):105.e1-105.e12. PubMed ID: 26829508
    [Abstract] [Full Text] [Related]

  • 19. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D, Moore RM, Mercer BM, Mansour JM, Mesiano S, Schatz F, Lockwood CJ, Moore JJ.
    Am J Obstet Gynecol; 2017 Dec 25; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [Abstract] [Full Text] [Related]

  • 20. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.
    Murphy CC, Cirillo PM, Krigbaum NY, Cohn BA.
    Am J Obstet Gynecol; 2022 Jan 25; 226(1):132.e1-132.e14. PubMed ID: 34767803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.